Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
10.92
+0.27 (2.54%)
Sep 22, 2026, 4:00 PM EDT - Market closed
Kazia Therapeutics Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Kazia Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $28.89. The average 1-year stock price forecast is 164.56% higher than the current stock price, while the lowest is $17.82 (+63.19%) and the highest is $39.96 (+265.93%).
Price Target: $28.89 (+164.56%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Kazia Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 3 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Buy Reiterates $40 | Buy | Reiterates | $40 | +266.30% | Sep 1, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $29 | Buy | Reiterates | $29 | +165.57% | Sep 1, 2026 |
| Maxim Group | Maxim Group | Buy Reiterates $30 | Buy | Reiterates | $30 | +174.73% | Jul 16, 2026 |
| Lake Street | Lake Street | Buy Initiates $32 | Buy | Initiates | $32 | +193.04% | Jun 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $18 | Buy | Reiterates | $18 | +64.84% | Jun 3, 2026 |
Financial Forecast
Revenue This Year
676.98K
from 1.83M
Decreased by -62.99%
Revenue Next Year
642.00K
from 676.98K
Decreased by -5.17%
EPS This Year
-0.05
EPS Next Year
n/a
from -0.05
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.